Enabling a phase 1 clinical trial of PACAB-002 and advancement of new product candidates

NaDeNo has been selected for the EIC Accelerator, one of Europe’s most competitive innovation funding programs. The blended finance award supports continued advancement of PACAB-002, our intraperitoneal nanoparticle therapy for ovarian cancer, through Phase 1, and positions NaDeNo as a Phase 2-ready company.

The EIC selection reflects external evaluation of the scientific merit, commercial potential, and execution capability of NaDeNo’s PACA nanomedicine platform.

Download full press release (PDF)

What this means:

• Up to €10 million in financing.
• PACAB-002 will enter into Phase 1 clinical trials in patients with advanced ovarian cancer — a major milestone toward clinical proof-of-concept.
• Strong external validation from one of Europe’s most competitive funding programs.
• Strengthens NaDeNo’s path toward becoming a Phase 2-ready company, while enabling continued expansion of the nanoparticle-based drug delivery platform.

Systemic therapies do not adequately reach micrometastases in the peritoneum — a key driver of relapse in high-grade serous ovarian cancer. PACAB-002 is designed for localized intraperitoneal delivery, enabling sustained drug exposure at tumor sites that intravenous treatment does not effectively address.

Want to know more? Contact us: contact@nadeno.com